A New Intervention for Implementation of Pharmacogenetics in Psychiatry: A Description of the PSY-PGx Clinical Study

Teuntje A. D. Pelgrim,Alexandra Philipsen,Allan H. Young,Mario Juruena,Ester Jimenez,Eduard Vieta,Marin Jukić,Erik Van der Eycken,Urs Heilbronner,Ramona Moldovan,Martien J. H. Kas,Raj R. Jagesar,Markus M. Nöthen,Per Hoffmann,Noam Shomron,Laura L. Kilarski,Thérèse van Amelsvoort,Bea Campforts,The PSY-PGx Consortium The PSY-PGx Consortium,Roos van Westrhenen

DOI: https://doi.org/10.3390/ph17020151

IF: 4.6

2024-01-24

Pharmaceuticals

Abstract:(1) Background Pharmacological treatment for psychiatric disorders has shown to only be effective in about one-third of patients, as it is associated with frequent treatment failure, often because of side effects, and a long process of trial-and-error pharmacotherapy until an effective and tolerable treatment is found. This notion emphasizes the urgency for a personalized medicine approach in psychiatry. (2) Methods This prospective patient- and rater-blinded, randomized, controlled study will investigate the effect of dose-adjustment of antidepressants escitalopram and sertraline or antipsychotics risperidone and aripiprazole according to the latest state-of-the-art international dosing recommendations for CYP2C19 and CYP2D6 metabolizer status in patients with mood, anxiety, and psychotic disorders. A total sample of N = 2500 will be recruited at nine sites in seven countries (expected drop-out rate of 30%). Patients will be randomized to a pharmacogenetic group or a dosing-as-usual group and treated over a 24-week period with four study visits. The primary outcome is personal recovery using the Recovery Assessment Scale as assessed by the patient (RAS-DS), with secondary outcomes including clinical effects (response or symptomatic remission), side effects, general well-being, digital phenotyping, and psychosocial functioning. (3) Conclusions This is, to our knowledge, the first international, multi-center, non-industry-sponsored randomized controlled trial (RCT) that may provide insights into the effectiveness and utility of implementing pharmacogenetic-guided treatment of psychiatric disorders, and as such, results will be incorporated in already available dosing guidelines.

pharmacology & pharmacy,chemistry, medicinal

What problem does this paper attempt to address?

The problem that this paper attempts to solve is that in the treatment of mental illness, the effectiveness of drug treatment has only been confirmed in about one - third of patients, and frequent treatment failures are often related to side effects, and finding effective and tolerable treatment regimens requires a long trial - and - error process. This emphasizes the urgency of implementing personalized medical approaches in psychiatry. Specifically, the paper describes a clinical study named PSY - PGx, which aims to investigate the effects of pharmacogenomics - based dose adjustments of antidepressants (escitalopram and sertraline) or antipsychotics (risperidone and aripiprazole) for patients with mood disorders, anxiety disorders and psychotic disorders according to the latest international dose recommendation standards. The goal of this study is to evaluate the effectiveness and practicality of pharmacogenomics in psychiatry by comparing the results of individualized drug doses guided by pharmacogenomics with those of conventional dose prescriptions. The primary outcome measure is the patient - reported personal recovery, and the secondary outcome measures include clinical efficacy (response or symptom remission), side effects, general health status and psychosocial function.